Volume 63, Pages S73-S78 (June 2003)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz

Anemia management in chronic kidney disease

Volume 66, Issue 4, Pages (October 2004)

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Reassessment of the care of the patient with chronic kidney disease

Progression of renal failure and hypertensive nephrosclerosis

Volume 63, Pages S88-S90 (June 2003)

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Francesco Paolo Schena Kidney International

Need for better diabetes treatment for improved renal outcome

Volume 67, Issue 5, Pages (May 2005)

Volume 76, Pages S50-S99 (August 2009)

Volume 70, Pages S21-S25 (December 2006)

Metformin and other antidiabetic agents in renal failure patients

George A. Kaysen, Burl R. Don

Volume 72, Issue 9, Pages (November 2007)

Anemia as a risk factor for chronic kidney disease

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

Volume 70, Issue 11, Pages (December 2006)

The epidemiology of chronic kidney disease

Prevention of renal failure: The Malaysian experience

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

Volume 73, Pages S5-S17 (April 2008)

Acute myocardial infarction in patients with end-stage renal disease

Volume 70, Issue 12, Pages (December 2006)

Volume 76, Issue 6, Pages (September 2009)

Novel phosphate binders: plus ça change, plus c’est la même chose

New insights in uremic toxins

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Nephrology in Latin America, with special emphasis on Brazil

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Cardiovascular disease in pediatric chronic dialysis patients

Volume 68, Issue 3, Pages (September 2005)

AGEs in foods: Do they play a role in uremia?

The kidney, a cardiovascular risk marker, and a new target for therapy

Lynda Anne Szczech, Ira L. Lazar Kidney International

Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson Kidney International

Volume 73, Pages S72-S75 (April 2008)

Homocysteine, renal function, and risk of cardiovascular disease

Opportunities for a chronic disease outreach program in China

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Peritoneal dialysis in Mexico

Volume 63, Pages S79-S82 (June 2003)

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Low bone turnover in patients with renal failure

Volume 63, Issue 2, Pages (February 2003)

Pablo A. Ureña Torres, Marc De Broe Kidney International

Lanthanum pharmacokinetics: Are rat data misleading?

Volume 55, Pages S3-S16 (June 1999)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 57, Issue 3, Pages (March 2000)

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Changes to the End-Stage Renal Disease Quality Incentive Program

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Renal vascular disease in the elderly

Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis.

Cell biological and physicochemical aspects of arterial calcification

Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Ellen G. Neven, Marc E. De Broe, Patrick.

Volume 74, Issue 10, Pages (November 2008)

Volume 55, Pages S41-S46 (June 1999)

Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Danilo Fliser, Jan T. Kielstein, Hermann Haller, Stefanie M. Bode-Böger Kidney.

Presentation transcript:

Volume 63, Pages S73-S78 (June 2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients Patrick C. D'Haese, Goce B. Spasovski, Aleksander Sikole, Alastair Hutchison, Tony J. Freemont, Sylvie Sulkova, Charles Swanepoel, Svetlana Pejanovic, Llubica Djukanovic, Alessandro Balducci, Giorgio Coen, Waldysaw Sulowicz, Anibal Ferreira, Armando Torres, Slobodan Curic, Milan Popovic, Nada Dimkovic, Marc E. De Broe Kidney International Volume 63, Pages S73-S78 (June 2003) DOI: 10.1046/j.1523-1755.63.s85.18.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Comparison and temporal evolution of some relevant bone-related parameters in both study groups. Kidney International 2003 63, S73-S78DOI: (10.1046/j.1523-1755.63.s85.18.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Patients with either low bone turnover at baseline and those evolving toward low bone turnover at follow-up in both study groups are shown in the upper panels. Lower panels show temporal evolution of renal bone disease of all patients after one year of treatment with either lanthanum or calcium carbonate. Values between brackets indicate the prevalence of the various types of ROD. Kidney International 2003 63, S73-S78DOI: (10.1046/j.1523-1755.63.s85.18.x) Copyright © 2003 International Society of Nephrology Terms and Conditions